Quidel Corporation Authorizes Additional $25 Million under Stock Repurchase Program

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ:QDEL), a leader in point-of-care rapid diagnostic tests, today announced that its Board of Directors has authorized an extension of the Company's current common stock repurchase program. The repurchase plan is intended to increase shareholder value and reduce the dilutive effect of Quidel's equity compensation programs. The extension authorizes the repurchase of up to an additional $25 million in shares of Quidel common stock under the repurchase program.

Back to news